Jefferies initiated coverage of TransMedics (TMDX) with a Buy rating and $145 price target The company has developed “differentiated” technology and a service/ transport model, enabling higher utilization and greater penetration for livers, hearts, and lungs, the analyst tells investors in a research note. The firm sees above-consensus growth for TransMedics in 2027, driven by its next-generation heart and lung trials.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
- TransMedics added to ‘Tactical Underperform’ list at Evercore ISI
- TransMedics Group Acquires Aircraft for Organ Transport
- TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations
- TransMedics, Mercedes-Benz partner on organ transportation across Italy